Healthpoint, DFB to pay up to $48M in drug case

December 6, 2012

(AP)—Healthpoint Ltd. and DFB Pharmaceuticals will pay up to $48 million to settle allegations that Healthpoint marketed a prescription skin ointment without approval from federal regulators.

The Justice Department said Healthpoint caused false claims for reimbursement to be submitted to Medicare and Medicaid for Xenaderm, which is used for treating nursing home patients' bed sores. Fort Worth, Texas-based Healthpoint is one of DFB's operating companies.

The government alleged that Healthpoint's business strategy was to market new modeled after products that were available before October 1962 in order to avoid the time, effort and expense of obtaining approval from the . Products containing Xenaderm's principal were on the market before 1962, but the FDA determined the ingredient was less-than-effective for its intended use.

Explore further: Merck will pay $950M to settle Vioxx investigation

shares

Related Stories

Recommended for you

New research shows vaccine protection against Zika virus

June 28, 2016

The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. The World ...

Nearly 1 in 3 on Medicare got commonly abused opioids

June 22, 2016

Nearly 12 million Medicare beneficiaries received at least one prescription for an opioid painkiller last year at a cost of $4.1 billion, according to a federal report that shows how common the addictive drugs are in many ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.